H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Portage Biotech to $21 from $22 and keeps a Buy rating on the shares post the Q2 results.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRTG:
- Portage Biotech price target lowered to $18 from $26 at Cantor Fitzgerald
- Portage Biotech price target lowered to $18 from $26 at Oppenheimer
- Portage Biotech reports Q4 EPS (6c), consensus (29c)
- Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
- Portage Biotech participates in a conference call with Cantor Fitzgerald
